KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacific Biosciences Of California (PACB) Payables (2016 - 2025)

Historic Payables for Pacific Biosciences Of California (PACB) over the last 16 years, with Q3 2025 value amounting to $16.4 million.

  • Pacific Biosciences Of California's Payables rose 3562.67% to $16.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.4 million, marking a year-over-year increase of 3562.67%. This contributed to the annual value of $16.6 million for FY2024, which is 660.58% up from last year.
  • According to the latest figures from Q3 2025, Pacific Biosciences Of California's Payables is $16.4 million, which was up 3562.67% from $15.1 million recorded in Q2 2025.
  • Pacific Biosciences Of California's 5-year Payables high stood at $21.0 million for Q1 2024, and its period low was $3.5 million during Q1 2021.
  • For the 5-year period, Pacific Biosciences Of California's Payables averaged around $13.8 million, with its median value being $15.1 million (2025).
  • In the last 5 years, Pacific Biosciences Of California's Payables plummeted by 3597.36% in 2021 and then surged by 40726.02% in 2022.
  • Over the past 5 years, Pacific Biosciences Of California's Payables (Quarter) stood at $12.6 million in 2021, then grew by 13.62% to $14.3 million in 2022, then increased by 8.61% to $15.6 million in 2023, then increased by 6.61% to $16.6 million in 2024, then fell by 1.37% to $16.4 million in 2025.
  • Its Payables stands at $16.4 million for Q3 2025, versus $15.1 million for Q2 2025 and $14.0 million for Q1 2025.